Related Scientific Publications

28.05.2024 / Challenges in assessing the immunization status of adults in Germany—lessons from a population-based VACCELERATE survey on polio vaccination (Infection):

25.04.2024 / Coordination of COVID‑19 platform trials in Europe (Trials):

04.04.2024 / Perspectives of European Patient Advocacy Groups on Volunteer Registries and Vaccine Trials: VACCELERATE Survey Study (JMIR):

22.12.2023 / Immunogenicity, Reactogenicity and Safety of a Second Booster with BNT162b2 or Full-Dose mRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 Years (EU-COVAT-1-AGED Part B) (Preprints with The Lancet):

06.12.2023 / Predicting the next pandemic: VACCELERATE ranking of the World health Organization's Blueprint for action to prevent epidemics (Travel Medicine and Infectious Disease):

29.11.2923 / The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE Consortium (vaccines):

02.11.2023 / Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time (nature communications):

31.10.2023 / Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults 75 years (EU-COVAT-1) (Vaccine):

27.10.2023 / Epidemiology of Acute Respiratory Infection with SARS-CoV-2, Influenza A & B Viruses, Respiratory Syncytial Virus, and Adenovirus in VACCELERATE Volunteers in Germany (Preprints with THE LANCET):

01.09.2023 / Factors that impact on recruitment to vaccine trials in the context of a pandemic or epidemic: a qualitative evidence synthesis (Cochrane Library):

18.05.2023 / VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe (Vaccine):

03.04.2023 / Enhancing Public Health Communication Regarding Vaccine Trials: Design and Development of the Pan-European VACCELERATE Toolkit (JMIR Publications):

07.12.2022 / Efficacy and safety of COVID‐19 vaccines (Cochrane Library):

11.2022 / Performance and validation of an adaptable multiplex assay for detection of serologic response to SARS-CoV-2 infection or vaccination (Journal of Immunological Methods):

10.2022 / Monkeypox diagnostic and treatment capacity at epidemic onset: A VACCELERATE online survey (Journal of Infection and Public Health):

08.10.2022 / A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network (Trials):

04.10.2022 / Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2 (eBioMedicine):

19.09.2022 / Monkeypox in children and adult women in Europe: Results from a flash VACCELERATE pilot survey (Enfermedades Infecciosas y Microbiología Clínica):

31.08.2022 / Vaccination rates in Europe are not associated with online media intensity (JCOM Journal of Science Communication):

18.06.2022 / A pilot surveillance report of SARS-CoV-2 rapid antigen test results among volunteers in Germany, 1st week of July 2022 (Infection):

13.06.2022 / Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR (Nature Biotechnology):

02.06.2022 / VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment (Vaccine):

05.04.2022 / A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern (Communications Medicine):

23.03.2022 / Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination (Frontiers in Immunology):

11.01.2022 / Factors that impact on recruitment to vaccine trials during a pandemic or epidemic: a qualitative evidence synthesis (Cochrane Library):

04.10.2021 / Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days (Frontiers in Immunology):

03.08.2021 / Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals (Cell Reports):

29.07.2021 / Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 (The Lancet Infectious Diseases):

27.05.2021 / Reactogenicity and Immunogenicity of BNT162b2 in Subjects Having Received a First Dose of ChAdOx1s: Initial Results of a Randomised, Adaptive, Phase 2 Trial (CombiVacS) (The Lancet):